DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

DarioHealth (NASDAQ: DRIO), a leader in the global digital-therapeutics (“DTx”) market, today announced its entry into an agreement with one of the largest U.S. national health plans to offer its self-insured employer customers the Dario digital behavioral health solution as part of its behavioral health offering. According to the update, initial members are expected on the platform in the fourth fiscal quarter of 2021, with additional rollout anticipated over the course of 2022.

DarioHealth Corp. Enters Landmark Agreement with Leading National Health Plan

The stock price of DarioHealth Corp (NASDAQ: DRIO) increased by over 10% pre-market today. This is why it happened.

DRIO Stock: Why It Increased Today

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it has entered into an agreement with one of the largest U.S. national health plans ("Plan") to offer its self-insured employer customers the Dario digital behavioral health solution as part of its behavioral health offering.  Initial members are expected on the platform in the fourth fiscal quarter of 2021, with additional rollout anticipated over the course of 2022.

DarioHealth Announces Agreement with Leading National Health Plan

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today an agreement with a global company based in the United States ("Company") to provide its integrated digital health management solution for diabetes, hypertension, and musculoskeletal (MSK) health. The contract is expected to launch in the first quarter of 2022.

DarioHealth Announces Agreement with Global Employer for Metabolic and Musculoskeletal Health Solutions

NEW YORK, Sept. 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in a fireside chat during the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being held September 27-30, 2021.

DarioHealth to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company's Chief Medical Officer, Dr. Omar Manejwala, will present at the annual American Health Insurance Plans National Conference on Medicare, Medicaid and Dual Eligibles being held virtually on September 22 nd, 2021 at 12:45 p.m.

DarioHealth Chief Medical Officer Dr. Omar Manejwala to Speak at American Health Insurance Plans National Conference on Medicare, Medicaid and Dual Eligibles

Dario Continues to Expand its Employer Contracts Across Broad Range of Solutions NEW YORK, Sept. 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its suite of digital therapeutics for diabetes, hypertension and pre-diabetes to a Northeast regional employer ("Employer").

DarioHealth Chosen by Northeast Regional Employer

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its digital behavioral health platform to a casino resort company ("Casino Resort Company") in California.

DarioHealth Selected by Another Employer for Behavioral Health Services

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has finalized a contract with PeopleOne Health to be the digital behavioral health solution of choice for patients effective in September 2021. PeopleOne Health is a regional care provider, and Dario's partnership with the company marks the company's continued expansion and growth in the provider market as it leverages its compelling proprietary product portfolio.

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Partners With Regional Primary Care Provider PeopleOne Health To Provide Digital Health Solutions

NEW YORK, Aug. 31, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has been selected by regional primary care provider PeopleOne Health to be the digital behavioral health solution of choice for patients beginning this September. This contract represents Dario's continuing growth in the provider market, leveraging its expanded product portfolio.

DarioHealth Chosen by Regional Primary Care Provider PeopleOne Health as its Digital Behavioral Health Partner

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2021 Results - Earnings Call Transcript

DarioHealth Corp (NASDAQ: DRIO) reported second-quarter FY21 revenue growth of 194% year-on-year to $5.26 million, beating the analyst consensus of $5.11 million. The non-GAAP billings rose 186% Y/Y to $5.13 million from higher sales and the consolidation of Upright revenues.

Why Is DarioHealth Falling After Earnings?

Shares of DarioHealth (NASDAQ:DRIO) fell 0.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.68), which beat the estimate of ($0.85).

Recap: DarioHealth Q2 Earnings

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the second quarter of 2021 and provided a corporate and commercial update. "During the second quarter and subsequent period, we saw increasing demand for our integrated multi condition digital therapeutics solution, driven in part by the expansion of our metabolic offering into musculoskeletal and pain conditions through the acquisition of Upright Technologies in February 2021 and into behavioral health through the acquisition of wayForward in June 2021," stated Erez Raphael, Chief Executive Officer of Dario.

DarioHealth Reports Strong Second Quarter 2021 Results and Operational Highlights

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference demonstrating the impact of Dario's intelligent personalization platform. Dario's latest presentation examined the impact of personalized clinical interventions delivered in real-time through the company's digital therapeutics platform.

DarioHealth Presents New Study Demonstrating Significant Clinical Impact of Personalized Digital Interventions Based on Real-Time Data

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the second quarter ended June 30, 2021 on Monday, August 16, 2021, and host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President and General Manager of North America, and Zvi Ben-David, Chief Financial Officer will host the call.

DarioHealth to Report Second Quarter 2021 Results on Monday, August 16

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as the digital behavioral health provider by a leading national professional services company.       This new contract represents the fourth employer to partner with Dario for its digital behavioral health services in the last month as improving access to mental health resources remains a top priority.

DarioHealth Behavioral Health Solution Selected by National Employer

NEW YORK, July 27, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced the launch of its digital behavioral health solution that now includes Workplace Options (WPO) services for its global users. WPO is the largest independent provider of integrated employee wellbeing solutions around the world.

DarioHealth Launches Behavioral Health Solutions Globally in New Partnership with Workplace Options

NEW YORK, July 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as a digital health provider by Alabama Regional Medical Services (ARMS), a Federally Qualified Health Center (FQHC) accredited by The Joint Commission and designated as a Primary Care Medical Home serving patients in Jefferson, Shelby, St. Clair, and Blount counties. ARMS selected Dario's Remote Patient Monitoring (RPM) to improve the management of hypertension across a diverse patient population, including large numbers of underserved and uninsured patients.

DarioHealth Chosen to Provide Remote Patient Monitoring for Alabama Regional Medical Services

NEW YORK , July 13, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced Chief Medical Officer Omar Manejwala, M.D. will present "Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System" during the virtual conference DTx Europe on July 14 th at 5:55 a.m.

DarioHealth Chief Medical Officer Omar Manejwala, M.D., to Present on the Role of Digital Therapeutics in Post-Pandemic Healthcare at DTx Europe

NEW YORK, July 12, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced the launch of three new employer client contracts, including one global partnership, for the Company's new behavioral health solution powered by wayForward.  These contracts are for a fixed monthly fee based on the number of employees with access to the behavioral health platform and are expected to contribute to revenue beginning in the third quarter of 2021.

DarioHealth Expands Employer Footprint with Three New Contracts

NEW YORK, June 29, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care.     Dario's latest research examines the impacts of the company's artificial intelligence (AI)-driven personalization engine on user engagement and clinical outcomes for close to 10,000 members.

New Research from DarioHealth Expands Evidence that Personalized Interventions Impact Health Behaviors and Improve User Engagement

NEW YORK, June 24, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as digital health provider by Coastal Family Health Center, a local, non-profit healthcare network providing comprehensive primary care to patients across several underserved counties in and around the Mississippi Gulf Coast.     The initial focus of the engagement will be Dario's Remote Patient Monitoring (RPM) solution for hypertension and the prevention of related cardiac events.

DarioHealth Remote Patient Monitoring Selected by Coastal Family Health Center to Improve Health of Patients with Hypertension

NEW YORK, June 16, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today the launch of the Upright GO S, a new wearable sensor based on the company's pioneering biofeedback technologies to make better back health accessible to more people.     This new product from Upright, by Dario, is part of the company's planned growth strategy for increasing platform membership across both business partnerships and consumer channels.

DarioHealth Expands Footprint in Musculoskeletal Sensor Technologies with the Upright GO S

NEW YORK, June 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the US equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on Friday, June 4, 2021. Annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 7, 2021, ranking them by total market capitalization.

News for DarioHealth Stock (DRIO)